PGx447:Exploratory genetic analysis of pazopanib (GW786034) related diarrhea in patient with RCC(VEG102616,VEG105192,VEG107769) (116054)

Study identification

• EU PAS number:
  EUPAS6234
• Study ID:
  40739
• Official title and acronym:
  PGx447:Exploratory genetic analysis of pazopanib (GW786034) related diarrhea in patient with RCC(VEG102616,VEG105192,VEG107769) (116054)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study status:
  Finalised

Research institutions and networks

Institutions

GlaxoSmithKline (GSK)

Study timelines

Date when funding contract was signed

Planned: 08/07/2011

Actual: 08/07/2011

Study start date

Planned: 10/11/2011

Actual: 10/11/2011

Date of final study report

Planned: 30/09/2012

Actual: 22/02/2012

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

GlaxoSmithKline

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)